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Intravenous immunoglobulins are considered as potential adjuvant therapy in sepsis patients. We 
present a narrative review of recent research into the associations between immunoglobulins and 
sepsis. 
Immunoglobulins and free light chains 
Immunoglobulins are glycoproteins secreted by plasma cells. Each immunoglobulin molecule 
monomer consists of identical heavy and light chain pairs held together by electrostatic forces and 
disulphide bonds. Based on their heavy chain, there are five immunoglobulin isotypes namely IgG, 
IgA, IgM, IgD and IgE [1]. There are two types of light chains (kappa and lambda), which are also 
present in circulation independent of whole immunoglobulin molecules, referred to as free light chains 
(FLC). The Variable regions of immunoglobulin molecules enable cross-linking to bacterial and other 
antigens (antigen binding). The Constant region transduces signals in response to antigen binding 
(effector function). IgG  has four subclasses (IgG1, IgG2, IgG3, and IgG4) and the main functions are 
secondary antibody responses, opsonisation and complement activation. IgA has two subclasses 
(IgA1, IgA2) and the main function is mucosal immunity. The key functions of IgM are complement 
activation and primary antibody responses. 
Low immunoglobulins and high free light chains are common in sepsis 
Low immunoglobulin concentrations [2] as well as abnormally high FLC levels [3] are seen in 
most adult sepsis patients. Although, low IgG is the commonest quantitative immunoglobulin 
abnormality in sepsis, a number of reasons explain why low IgG alone does not increase the risk of 
death in sepsis patients [2]. First, the nadir of immunoglobulin drop is often seen on day 3 following 
sepsis diagnosis [2, 3]. Second, low levels of multiple endogenous immunoglobulins (IgG1, IgM and 
IgA) may be required to increase the risk of death [2-4]. Third, the association between low 
immunoglobulins and mortality is observed in sepsis patients with less severe organ dysfunction [5]. 
These reasons suggest that the risk of death caused by low immunoglobulins is either lower than 
other stronger risk factors such as organ dysfunction / comorbidity in sepsis patients or that our 
understanding of the mechanisms behind this high prevalence of low immunoglobulins in sepsis is 
incomplete. For example, endothelial abnormalities in sepsis include endothelial dysfunction and 
endothelial apoptosis leading to leaky capillaries. IgG and albumin are recycled through the Fc 
neonatal receptors in endothelial cells. There may also be impaired immunoglobulin recycling and 
leak of immunoglobulin into the extra vascular space resulting in low immunoglobulin levels [1]. 
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Immunoglobulin consumption secondary to pathogen opsonisation and neutralisation of toxins could 
also contribute to low immunoglobulin levels. There is impaired in vitro IgM production by lymphocytes 
from sepsis patients [6]. In health, light chains are produced in excess of heavy chains. Raised light 
chains are surrogates for new immunoglobulin production [7]. Therefore, the observation that low 
immunoglobulin levels with concurrent raised FLC levels suggest impaired immunoglobulin assembly 
[3]. Importantly, raised FLC levels in sepsis could also result from release of stored light chains during 
accelerated B-lymphocyte death [8] and impaired excretion due to renal dysfunction, independent of 
immunoglobulin assembly.  
Intravenous immunoglobulins and previous clinical trials in adults with sepsis  
Intravenous immunoglobulins are produced by pooling together of serum immunoglobulins 
from multiple donors. There are two types of intravenous immunoglobulin products – IVIG containing 
only IgG and IVIGAM containing IgG, IgA, and IgM. The newer IVIGAM products contain higher levels 
of IgM. The manufacturing processes, concentrations of different immunoglobulins and the herd 
immunity of the donors influence the therapeutic effects of IVIG/IVIGAM [1]. The pleiotropic 
immunomodulatory properties of IVIG are mediated through Fc gamma receptors (FcγR), scavenging 
of mediators, by negating the biological effects of B-lymphocyte apoptosis and replenishing low 
immunoglobulins in sepsis [1]. Infection and sepsis increase leukocyte FcγR expression. As the 
relative expression of inhibitory FcγRIIB versus stimulatory FcγR in sepsis patients is unknown, the 
extent of immunomodulation with IVIG/IVIGAM therapy may unpredictably differ between patients.   
Systematic reviews of randomized controlled trials (RCTs) have showed potential benefits of 
IVIG/IGAM in sepsis, but important limitations preclude their utilization as a standard of care therapy 
in sepsis patients [9, 10]. Key limitations include variable trial quality, uncertainty around best 
responder characteristics, the ideal preparation IVIG vs IVIGAM, or the dosage regimen, timing, 
duration of therapy, low product availability and lack of cost effectiveness data (Table 1) [9, 10]. 
Importantly, although IVIG are often used in sepsis from group A streptococcus infection, the level of 
evidence that could support such recommendation is lower than for the overall population of patients 
with sepsis [9, 10].  In addition, IVIG/IVIGAM therapy is associated with adverse reactions such as 
fever, headache, thromboembolic events, renal dysfunction, aseptic meningoencephalitis, 
anaphylaxis, and detrimental effects of the positive fluid balance on outcomes such as respiratory 
dysfunction [9, 10]. These issues also highlight the need for better designed IVIG/IVIGAM trials. 
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Designing future intravenous immunoglobulins trials in sepsis 
Sepsis is a heterogeneous illness.  Sepsis characteristics such as site of infection and organ 
dysfunction influences mortality differently [11]. Sepsis related host responses differ by site of 
infection [12]. These differences may lead to different IVIG/IVGAM treatment effects in trials. These 
differences could also inform IVIG/IVIGAM treatment responder characteristics (predictive 
enrichment) or identify subpopulations (such as patients with exaggerated inflammation) who benefit 
the most in future trials [13]. As the biological rationale for IVIG/IVIGAM therapy is 
immunomodulation, the highest tolerated dose with the greatest potential effect need to be 
determined. Phase II clinical trials looking at identifying dominant mechanism affecting endogenous 
immunoglobulin pathways could also inform future trials. For example, patients with low levels of 
immunoglobulins with concurrently raised free light chains imply impaired immunoglobulin production 
which may be a major mechanism contributing to death in sepsis. Interventional cohort studies 
highlight the potential utility of immunoglobulin therapy in patients with multidrug resistant bacterial 
infections [14] and in patients with sepsis associated coagulopathy [15], which should be followed 
through to inform future immunoglobulin trials in sepsis. 
Conclusions 
Immunoglobulin and B-lymphocyte homeostasis is acutely altered in sepsis. Despite 
biological plausibility, further trials addressing the limitations in current evidence base are required 
prior to using intravenous immunoglobulins as adjuvant therapy for sepsis patients. 
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Table-1: Reasons precluding the current use of IVIG/IVGAM in sepsis [9] 
Parameter Explanation from previous trials 
Trial quality Many of these trials were small, were prone to bias primarily due to lack of blinding, had suboptimal adverse event reporting and had 
low quality when evaluated using standard randomised controlled trial quality assessment instruments. 
Population The trial populations varied in specific characteristics such as infection site, illness severity and organ dysfunction. In meta-analysis of 
trials, patients with higher illness severity (severe sepsis and shock vs. sepsis) were more likely to benefit from IVIG/IVIGAM therapy. 
Product In meta-analysis of trials, IVIGAM had a higher treatment effect compared to IVIG, albeit with significant between trial heterogeneity. 
Thus, the ideal therapeutic product to use in sepsis patients is unknown. Further, the IVIG/IVIGAM products used differed between trials 
and this may have contributed to differences in the beneficial (and/or adverse) immunomodulatory effects. 
Dosing, timing and 
duration of therapy 
Trials have tested widely different IVIG/IVIGAM doses (between 0.2 to 2 g/kg) and different treatment durations (from 2 to 7 days). At 
low doses only replacement of low immunoglobulin levels is achieved. For immunomodulation, doses greater than 0.5g/kg are required. 
In meta-analysis of trials, patients receiving higher doses (≥1 g/kg vs. <1 g/kg) over a longer period (more than 2 days) may benefit 
more from IVIG/IVIGAM therapy. 
Mechanism of 
action 
Exact mechanism(s) by which intravenous immunoglobulins provide benefit to sepsis patients are unclear. Therefore, no trial to date 
had targeted or evaluated specific mechanisms, other than generic improvements in inflammation. 
Adverse effects Although IVIG/IVIGAM products have several adverse effects well observed in clinical studies. Some of the adverse effect overlap with 
sepsis manifestations and as such the safety of these products still remains uncertain.   
Availability and 
costs 
IVIG/IVGAM being a blood product coming from several human donors, its production is resource intensive, costly and limited in 
capacity. The cost effectiveness of IVIG/IVIGAM in sepsis remains uncertain. 
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Standard of care Most trials were conducted more than a decade ago, when the standard of early sepsis management (resuscitation goals, fluids and 
antibiotic therapy) were different. Therefore, an argument often highlighted is that the IVIG/IVIGAM treatment effects were observed in 
the context of a suboptimal early sepsis care. 
 
 
